Arimoto T, Yoshikawa T, Komori Y, Kumagai Y
First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
Life Sci. 1996;59(12):953-9. doi: 10.1016/0024-3205(96)00413-4.
We evaluated the inhibitory action of benexate (benzyl 2-[trans-4 -(guanidinomethyl) cyclohexylcarbonyloxy] benzoate hydrochloride beta-cyclodextrin clathrate), an anti-ulcer agent, on the formation of nitric oxide by stomach and brain enzyme preparations and on the purified neuronal nitric oxide synthase (NOS). Benexate markedly inhibited NOS activities of both stomach and brain preparations, with IC50 values of 68 and 29 microM, respectively. The results of double-reciprocal analysis suggested that the inhibition was competitive with an arginine substrate. Experiments with purified NOS revealed that benexate suppressed not only citrulline formation but also the oxidation of NADPH and the production of hydrogen peroxide by the enzyme. Taken together, it is indicated that benexate is an inhibitor for NOS in spite of the fact the drug elicits an increase in blood flow in a gastric mucosa.
我们评估了抗溃疡药物贝奈酯(盐酸苄基 2 - [反式 - 4 -(胍基甲基)环己基羰基氧基]苯甲酸酯β - 环糊精包合物)对胃和脑酶制剂中一氧化氮形成以及对纯化的神经元型一氧化氮合酶(NOS)的抑制作用。贝奈酯显著抑制胃和脑制剂的 NOS 活性,IC50 值分别为 68 和 29 μM。双倒数分析结果表明,该抑制作用与精氨酸底物存在竞争性。对纯化的 NOS 进行的实验显示,贝奈酯不仅抑制瓜氨酸的形成,还抑制该酶对 NADPH 的氧化以及过氧化氢的产生。综合来看,表明贝奈酯是一种 NOS 抑制剂,尽管该药物会引起胃黏膜血流增加。